SPPAM
HRMY icon

Summit Partners Public Asset Management’s Harmony Biosciences HRMY Stock Holding History

Summit Partners Public Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-256,942
Closed -$9.29M – 106
2020
Q4 		$9.29M Buy
+256,942
New +$10.4M 0.41% 67

Other funds holding HRMY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
NP
Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Summit Partners Public Asset Management's HRMY Position: Q1 2021 in Review

Summit Partners Public Asset Management sold out of Harmony Biosciences (HRMY) in Q1 2021, closing a stake of 256,942 shares — an estimated $9.29M sold.

Summit Partners Public Asset Management first reported a position in HRMY in Q4 2020 and held it in 1 quarter. The position peaked at $9.29M in Q4 2020. 57 funds tracked by Wall St. Rank hold HRMY as of Q1 2021.

  • Summit Partners Public Asset Management reported no remaining Harmony Biosciences position as of Q1 2021 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 256,942 Harmony Biosciences shares in Q1 2021, an estimated $9.29M.
  • Summit Partners Public Asset Management first reported a position in Harmony Biosciences in Q4 2020 and held it in 1 quarter.
  • Summit Partners Public Asset Management's Harmony Biosciences position peaked at $9.29M in Q4 2020.
  • 57 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2021.

Based on Summit Partners Public Asset Management's 13F filing for Q1 2021, filed 17 May 2021.